BPMC:NSD-Blueprint Medicines Corp (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 90.63

Change

-3.74 (-3.96)%

Market Cap

USD 5.61B

Volume

0.93M

Analyst Target

USD 97.36
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-08 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+3.79 (+0.93%)

USD 104.84B
REGN Regeneron Pharmaceuticals Inc

+3.29 (+0.45%)

USD 78.92B
ARGX argenx NV ADR

+0.64 (+0.10%)

USD 36.54B
ALNY Alnylam Pharmaceuticals Inc

+4.60 (+1.95%)

USD 30.22B
MRNA Moderna Inc

-4.36 (-9.17%)

USD 18.29B
UTHR United Therapeutics Corporatio..

+4.28 (+1.18%)

USD 15.91B
RPRX Royalty Pharma Plc

+0.16 (+0.61%)

USD 15.05B
SMMT Summit Therapeutics PLC

+0.66 (+3.63%)

USD 13.43B
INCY Incyte Corporation

-0.06 (-0.08%)

USD 13.41B
BMRN Biomarin Pharmaceutical Inc

+0.48 (+0.71%)

USD 12.74B

ETFs Containing BPMC

WDNA:LSE WisdomTree BioRevolution .. 2.71 % 0.00 %

-0.13 (-0.12%)

N/A
WDNA WisdomTree BioRevolution .. 2.53 % 0.00 %

-0.02 (-0.12%)

USD 2.18M
WBIO:LSE WisdomTree BioRevolution .. 2.45 % 0.00 %

+5.30 (+-0.12%)

USD 0.45M
WRNA:XETRA WisdomTree BioRevolution .. 2.35 % 0.00 %

N/A

USD 2.77M
CNCR Loncar Cancer Immunothera.. 1.70 % 0.79 %

-0.39 (-0.12%)

USD 0.01B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 3.91% 60% D- 76% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 3.91% 60% D- 76% C+
Trailing 12 Months  
Capital Gain 8.94% 70% C- 63% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 8.94% 70% C- 60% D-
Trailing 5 Years  
Capital Gain 10.23% 79% B- 59% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 10.23% 79% B- 52% F
Average Annual (5 Year Horizon)  
Capital Gain 16.02% 62% D 69% C-
Dividend Return 16.02% 62% D 68% D+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 50.33% 64% D 38% F
Risk Adjusted Return 31.82% 86% B+ 63% D
Market Capitalization 5.61B 96% N/A 89% A-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.